Author

P. Ballester

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

G. Ghislat· 2 shared A. S. Cheema· 1 shared B. Malissen· 1 shared C. Dong· 1 shared C. Verthuy· 1 shared E. Baudoin· 1 shared E. Pasquier· 1 shared F. Devred· 1 shared

Activity by Year

2020-2020 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

G. Ghislat

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

An NF-κB/IRF1 axis programs cDC1s to drive anti-tumor immunity

G. Ghislat, A. S. Cheema, E. Baudoin, C. Verthuy, P. Ballester, K. Crozat, N. Attaf, C. Dong, P. Milpied, B. Malissen, N. Auphan-Anezin, T.-P. V. Manh, M. Dalod, T. Lawrence

This study identifies the NF-κB/IRF1 axis as critical for cDC1 maturation and anti-tumor immunity, showing its role in CD8+ T cell activation and tumor control.

bioRxiv · Dec 28, 2020Immunology

Characterizing the relationship between the chemical structures of drugs and their activities on primary cultures of pediatric solid tumors

S. Simeon, G. Ghislat, P. Ballester

The paper analyzes drug activity data from pediatric solid tumor cultures to identify structural features associated with potency and develops QSAR models for drug repositioning.

bioRxiv · Oct 31, 2020Pharmacology & Toxicology

In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor

J. Ariey-Bonnet, K. Carrasco, M. Le Grand, L. Hoffer, S. Betzi, M. Feracci, P. Tsvetkov, F. Devred, Y. Collette, X. Morelli, P. Ballester, E. Pasquier

This paper identifies mebendazole as a potent MAPK14 inhibitor through in silico target prediction and experimental validation, revealing its potential for repurposing in brain tumor treatment.

bioRxiv · May 18, 2020Pharmacology & Toxicology